A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

Scientists discover that loss of MTAP gene disables immune defenses in tumors; DFMO drug could reactivate STING pathway.

A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...

An analysis of patient records suggests that mRNA covid-19 vaccines boost the immune response to cancerous tumours when given ...

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ...